Preferred Label : Anti-TREM1 Agonistic Monoclonal Antibody PY159;
NCIt definition : A humanized agonistic monoclonal antibody targeting triggering receptor expressed
on myeloid cells 1 (TREM1), with potential immunomodulating and antineoplastic activities.
Upon administration, anti-TREM1 agonistic monoclonal antibody PY159 targets, binds
to, crosslinks and activates TREM1 located on immunosuppressive tumor-associated myeloid
cells within the tumor microenvironment (TME), including monocytic myeloid derived
suppressor cells (mMDSCs), tumor associated neutrophils (TANs), and tumor associated
macrophages (TAMs). This activates TREM1-mediated signaling through the TREM1/DNAX
activating protein of 12kDa (DAP12) complex. This reprograms and repolarizes the immunosuppressive
myeloid cells, thereby inducing a pro-inflammatory state in these cells and altering
the TME. This stimulates anti-tumor immune responses leading to tumor cell destruction.
TREM1, an immunoglobulin (Ig) superfamily transmembrane protein constitutively expressed
on the cell surface of peripheral blood monocytes and neutrophils, is expressed within
the TME and is associated with poorer patient outcomes. Activation of TREM1 may amplify
immune responses.;
Molecule name : PY-159; PY 159;
NCI Metathesaurus CUI : CL1647924;
Origin ID : C178293;
UMLS CUI : C5554922;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
